Pemvidutide Guide
Pemvidutide: the GLP-1/glucagon agonist aimed at fat and liver
GLP-1 + glucagon
dual agonist
~15%
phase 2 weight loss range
Muscle-sparing
the distinctive claim
Pemvidutide is an investigational once-weekly GLP-1/glucagon dual agonist from Altimmune, developed for obesity and metabolic liver disease (MASH). It is not approved: everything known comes from its trial program. Its phase 2 obesity results landed in the mid-teens percent for weight loss, and its most-discussed feature is a claim that a high proportion of the weight lost was fat rather than lean mass, an appealing angle given the muscle-loss worries that shadow the whole class. The glucagon arm also targets liver fat directly, and as with other glucagon-containing agents, trials watch heart rate and the class-standard gastrointestinal effects.
Highlights
Key takeaways
- 01
Pemvidutide is investigational (Altimmune), not approved or prescribable; all data is from trials.
- 02
It is a GLP-1/glucagon dual agonist: GLP-1 for appetite, glucagon for energy expenditure and direct liver-fat effects.
- 03
Phase 2 obesity weight loss landed in the mid-teens percent, competitive within the emerging field.
- 04
Its headline claim is favorable body composition: a high share of weight lost reported as fat rather than lean mass, a notable angle given class-wide muscle-loss concerns.
- 05
MASH (metabolic liver disease) is a second major target, with the glucagon arm acting on liver fat.
- 06
Reported side effects are the class GI list during escalation, plus a monitored heart-rate increase from glucagon activity.
Pemvidutide at a glance: what trials have reported
| Aspect | What trials reported | Context |
|---|---|---|
| Mechanism | GLP-1 + glucagon dual agonist | Glucagon adds energy-expenditure and liver effects |
| Weight loss (obesity) | Mid-teens % in phase 2 | Competitive in the emerging class |
| Body composition | High proportion of loss as fat | The distinctive, if preliminary, claim |
| Liver disease (MASH) | Under study, liver-fat target | Second major indication |
| Common side effects | Nausea, vomiting, diarrhea | Escalation-focused, mostly mild-moderate |
| Heart rate | Monitored increase | Glucagon-class watch-item |
Drawn from published phase 2 data and program communications. Investigational figures shift as trials read out; nothing here is prescribing information or a basis for seeking the compound outside trials.
What is pemvidutide?
Pemvidutide is a once-weekly investigational injection that activates both the GLP-1 and glucagon receptors, developed by Altimmune for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). GLP-1 supplies the familiar appetite and gastric effects; glucagon is harnessed for energy expenditure and a direct effect on liver fat.
It sits in the same GLP-1/glucagon tier as survodutide and mazdutide, part of the wave of dual agonists chasing deeper metabolic effects than GLP-1 alone.
The muscle-sparing claim
Pemvidutide's most talked-about feature is body composition. Rapid weight loss on any drug risks taking lean mass with the fat, a worry we cover in our GLP-1 muscle-loss guide, and Altimmune has reported that a high proportion of the weight lost with pemvidutide was fat rather than lean tissue.
If that holds up in larger trials, it would be a genuinely attractive property, since the quality of weight loss, not just the amount, shapes how a result looks and holds. The honest caveat: this is preliminary trial data, and body-composition claims need phase 3 confirmation before they are more than promising.
What trials have shown
In phase 2 obesity trials, pemvidutide produced average weight loss in the mid-teens percent, placing it competitively within the emerging class. Its MASH program targets liver fat directly through the glucagon arm.
As with any phase 2 result, these are dose-finding numbers in limited populations, and phase 3 is what turns them into an approvable, fully characterized medicine.
Side-effect profile
The reported side effects are the class standard: gastrointestinal events, nausea, vomiting, and diarrhea, concentrated during dose escalation and mostly mild to moderate. Gentle titration reduces them, as across the class.
The glucagon component brings the same monitored heart-rate consideration seen with other glucagon-containing agents. Full safety characterization awaits the phase 3 readouts.
Cautions worth carrying
Expect the incretin-class cautions in any eventual label (pancreatitis vigilance, gallbladder risk with rapid loss, the thyroid C-cell lineage), plus specific heart-rate attention from the glucagon activity.
And the market caution: pemvidutide is not purchasable legitimately. Anything sold under the name is unregulated gray-market chemistry with no oversight, a serious risk for a potent investigational dual agonist.
Worth knowing before the headlines sweep you up
- Pemvidutide is investigational: no approval, no prescribing information yet
- Online pemvidutide is gray-market chemistry with zero oversight
- Trial GI effects were real and escalation-focused
- Heart-rate increase is a specific glucagon-class watch-item
- The muscle-sparing claim is promising but preliminary, pending phase 3
- Approved options exist today; waiting untreated has its own costs
When could it arrive, and what now?
Phase 3 readouts and regulatory review set the timeline; no approval exists yet. Until then the approved incretins are the real options.
If pemvidutide eventually matters to you, the preparation is unchanged: build the habits that make any of these drugs work (protein, training, tracking) on whatever you and your prescriber choose now. DoseLog carries them forward to whatever comes next.
FAQ
Frequently asked questions
What is pemvidutide?
An investigational once-weekly GLP-1/glucagon dual agonist from Altimmune, developed for obesity and metabolic liver disease (MASH). Phase 2 reported mid-teens percent weight loss; it is not approved, with phase 3 ahead.
Does pemvidutide preserve muscle?
Altimmune has reported that a high proportion of the weight lost was fat rather than lean mass, an appealing claim given class-wide muscle-loss concerns. It is preliminary trial data and needs phase 3 confirmation before it is established.
What are pemvidutide's side effects?
Trials report the class-standard GI list (nausea, vomiting, diarrhea) during escalation, mostly mild to moderate, plus a monitored heart-rate increase from the glucagon activity. Full safety data awaits phase 3.
When will pemvidutide be available?
Only after phase 3 readouts and regulatory review; no approval exists yet. Anything sold as pemvidutide before approval is unregulated and unsafe to use.
Track your GLP-1 journey on one quiet line.
Log your shot, injection site, meals, and side-effect severity together, and walk into your next appointment with a week-by-week picture instead of a guess.
Sources
- 1.Altimmune phase 2 obesity trial of pemvidutide (MOMENTUM) and program communications. Find on PubMed ↗
- 2.Pemvidutide MASH program data on liver-fat outcomes. Find on PubMed ↗
- 3.Reviews of GLP-1/glucagon dual-agonist pharmacology and body-composition outcomes. Find on PubMed ↗
This guide is for general education and is not medical advice. It doesn't account for your personal medical history, other medications, or your individual situation, and it doesn't replace a conversation with your doctor or pharmacist. Do not start, stop, or change the dose of GLP-1 or any medication based on what you read here. If you think you have a medical emergency, call your local emergency number. DoseLog is a tracking app; drug and company names are used factually under nominative fair use, and DoseLog is not affiliated with, endorsed by, or sponsored by any manufacturer mentioned.
Keep reading
CagriSema Guide
CagriSema: semaglutide plus amylin, and what trials report
Survodutide Guide
Survodutide: the GLP-1/glucagon dual agonist in late trials
Mazdutide Guide
Mazdutide: the GLP-1/glucagon agonist approved first in China
Amycretin Guide
Amycretin: the GLP-1/amylin combo in oral and injectable trials